The effects of vasopressin V2-receptor antagonist for cirrhosis patients with ascites were assessed by analyzing the improvement of ascites and serum sodium, changes of other correlative laboratory tests, and survival data from selected studies. Here, AVPR2 is linked to Cirrhosis.